HEPATOLOGÍA EXPERIMENTAL Y VECTORIZACIÓN DE FÁRMACOS
HEVEFARM
Instituto de Investigación Biomédica de Salamanca
Salamanca, EspañaPublicaciones en colaboración con investigadores/as de Instituto de Investigación Biomédica de Salamanca (9)
2023
-
Evaluation of potential targets to enhance the sensitivity of cholangiocarcinoma cells to anticancer drugs
Biomedicine and Pharmacotherapy, Vol. 168
-
Relevance of the organic anion transporting polypeptide 1B3 (OATP1B3) in the personalized pharmacological treatment of hepatocellular carcinoma
Biochemical Pharmacology, Vol. 214
2020
-
C3G contributes to platelet activation and aggregation by regulating major signaling pathways
Signal Transduction and Targeted Therapy, Vol. 5, Núm. 1
-
Patients with Cholangiocarcinoma Present Specific RNA Profiles in Serum and Urine Extracellular Vesicles Mirroring the Tumor Expression: Novel Liquid Biopsy Biomarkers for Disease Diagnosis
Cells, Vol. 9, Núm. 3
2018
-
C3G, through its GEF activity, induces megakaryocytic differentiation and proplatelet formation
Cell Communication and Signaling, Vol. 16, Núm. 1
2017
-
C3G promotes a selective release of angiogenic factors from activated mouse platelets to regulate angiogenesis and tumor metastasis
Oncotarget, Vol. 8, Núm. 67, pp. 110994-111011
2015
-
p38 MAPK down-regulates fibulin 3 expression through methylation of gene regulatory sequences: Role in migration and invasion
Journal of Biological Chemistry, Vol. 290, Núm. 7, pp. 4383-4397
2014
-
Polycystic liver diseases: Advanced insights into the molecular mechanisms
Nature Reviews Gastroenterology and Hepatology, Vol. 11, Núm. 12, pp. 750-761
2012
-
C3G transgenic mouse models with specific expression in platelets reveal a new role for C3G in platelet clotting through its GEF activity
Biochimica et Biophysica Acta - Molecular Cell Research, Vol. 1823, Núm. 8, pp. 1366-1377